We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety and Effects of Supplementation With Ergocalciferol on Erythropoietin Dosing in Hemodialysis Patients

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01395823
First Posted: July 18, 2011
Last Update Posted: March 14, 2016
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Dialysis Clinic, Inc.
Results First Submitted: January 8, 2016  
Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor);   Primary Purpose: Treatment
Condition: End Stage Renal Disease
Interventions: Dietary Supplement: ergocalciferol supplementation
Other: placebo

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
470 subjects were enrolled in the study; however 151 subjects did not make it to randomization due to EPO criteria not met n=45, did not meet other inclusion criteria n=57, no was reason provided n=49. Of the 319 subjects randomized, 43 had a baseline 25(OH)D >30. This analysis only pertains to the 276 subjects with a baseline 25(OH)D ≤30.

Reporting Groups
  Description
Ergocalciferol Supplementation ergocalciferol supplementation: 50,000 IU given either weekly; weekly for 3 months then monthly for 3 months; monthly
Placebo placebo: placebo pill given weekly, weekly for 3 months then monthly for 3 months; monthly

Participant Flow:   Overall Study
    Ergocalciferol Supplementation   Placebo
STARTED   137   139 
COMPLETED   122   130 
NOT COMPLETED   15   9 
Death                4                4 
Physician Decision                3                1 
Lost to Follow-up                1                0 
Transplant                1                0 
GI symptoms                1                0 
Withdrawal by Subject                5                4 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Ergocalciferol Supplementation ergocalciferol supplementation: 50,000 IU given either weekly; weekly for 3 months then monthly for 3 months; monthly
Placebo placebo: placebo pill given weekly, weekly for 3 months then monthly for 3 months; monthly
Total Total of all reporting groups

Baseline Measures
   Ergocalciferol Supplementation   Placebo   Total 
Overall Participants Analyzed 
[Units: Participants]
 137   139   276 
Age 
[Units: Years]
Mean (Standard Deviation)
 61.4  (13.3)   60.8  (13.9)   61.1  (13.6) 
Gender 
[Units: Participants]
     
Female   67   58   125 
Male   70   81   151 
Race (NIH/OMB) 
[Units: Participants]
     
American Indian or Alaska Native   0   0   0 
Asian   8   7   15 
Native Hawaiian or Other Pacific Islander   0   0   0 
Black or African American   76   90   166 
White   51   41   92 
More than one race   0   0   0 
Unknown or Not Reported   2   1   3 
Region of Enrollment 
[Units: Participants]
     
United States   137   139   276 
25Vit D (ng/mL) 
[Units: ng/mL]
Mean (Standard Deviation)
 16.0  (5.9)   16.9  (6.4)   16.4  (6.2) 
Epogen Dose, units/week 
[Units: Units/week]
Median (Inter-Quartile Range)
 5800 
 (2600 to 12200) 
 5400 
 (2400 to 11500) 
 5550 
 (2500 to 11900) 


  Outcome Measures

1.  Primary:   EPO Dose   [ Time Frame: Baseline, 6 months ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.


Results Point of Contact:  
Name/Title: Karen Majchrzak
Organization: Dialysis Clinic Inc
phone: 615-342-0483
e-mail: karen.majchrzak@dciinc.org



Responsible Party: Dialysis Clinic, Inc.
ClinicalTrials.gov Identifier: NCT01395823     History of Changes
Other Study ID Numbers: DCI-0002
First Submitted: July 14, 2011
First Posted: July 18, 2011
Results First Submitted: January 8, 2016
Results First Posted: March 14, 2016
Last Update Posted: March 14, 2016